Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

624 results
Display

Hepatitis B vaccination and immunotherapies: an update

Stasi C, Silvestri , Voller F

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease

Kim SU, Jeon MY, Lim TS

BACKGROUND/AIMS: The utility of asialo-α1-acid glycoprotein (AsAGP) for assessing the fibrotic burden is unknown. This study examined the diagnostic performance of the AsAGP level for advanced liver fibrosis or cirrhosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B

Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU

BACKGROUND/AIMS: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (Rad(CT) score) in patients with chronic hepatitis B (CHB)-related cirrhosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand

Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol , Piratvisuth T

BACKGROUND/AIMS: Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B

Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY

Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Biomarkers of Chronic Hepatitis B

Mak LY, Seto WK, Fung J, Yuen MF

Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Potential Therapies for Chronic Hepatitis B

Yoo SH, Kwon JH

A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients

Yoon EL

Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma

Lee HW

Multiple studies have shown that oral antiviral therapies reduced the incidence of hepatocellular carcinoma (HCC) and improved the survival of patients with chronic hepatitis B when compared with that of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Natural History and Treatment Indications of Chronic Hepatitis B

Sinn DH

HBV is the most common etiology of both liver cirrhosis and hepatocellular carcinoma in Korea. Despite much progress made, the currently available antiviral therapies cannot eradicate or eliminate this virus....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A case report of bleeding from duodenal varices treated with percutaneous transhepatic obliteration

Lee JH, Kim TH, Choi JW, Kim SY, Choi JY, Lee CK, Park BK, Chung JB

Duodenal varices are ectopic in nature and account for 40% of all ectopic bleeding cases. Ectopic variceal bleeding is rare (1%–5% of all variceal bleeding cases). The three principle approaches...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity

Wu S, Tu R, Liang X

PURPOSE: This study was conducted to investigate whether the presence of patchy echogenicity in the liver of patients with chronic hepatitis B (CHB) is predictive of liver stiffness. METHODS: A total...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B

Choi EJ, Kim JH, Han MS

BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Cho YY, Choi YH, Yu SJ, Cho EJ, Lee JH, Kim YJ, Yoon JH

BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU

BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Yu JH, Lee JW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?

Hanouneh I, Alkhouri N, Singal AG

Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The epidemiology of hepatitis B virus infection in Korea

Yim SY, Kim JH

The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Liver Cancer Association (KLCA), National Cancer Center (NCC), Goyang, Korea

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice

Song JE, Lee CH, Kim BS

BACKGROUND/AIMS: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr